作为肌肉骨骼肿瘤靶点的Rank配体
Rank ligand as a target in musculoskeletal neoplasms.
作者信息
Cote Gregory M
机构信息
Massachusetts General Hospital Cancer Center, Boston, MA, USA.
出版信息
Curr Rev Musculoskelet Med. 2015 Dec;8(4):339-43. doi: 10.1007/s12178-015-9310-y.
Abstract
Receptor activator of nuclear factor-κB ligand (RANKL) is a tumor necrosis factor (TNF) family member, which signals through the osteoclast surface RANK. As such, RANKL is required for osteoclast differentiation and function, namely bone resorption. There is now growing evidence that RANKL is a therapeutic target for musculoskeletal neoplasms, namely giant cell tumor of bone (GCTB) and osteosarcoma.
摘要
核因子κB受体活化因子配体（RANKL）是肿瘤坏死因子（TNF）家族成员，通过破骨细胞表面的RANK发出信号。因此，RANKL是破骨细胞分化和功能（即骨吸收）所必需的。现在越来越多的证据表明，RANKL是肌肉骨骼肿瘤，即骨巨细胞瘤（GCTB）和骨肉瘤的治疗靶点。
相似文献
1
Rank ligand as a target in musculoskeletal neoplasms.
Curr Rev Musculoskelet Med. 2015 Dec;8(4):339-43. doi: 10.1007/s12178-015-9310-y.
2
RANK and RANK ligand expression in primary human osteosarcoma.
J Bone Oncol. 2015 Jul 29;4(3):59-68. doi: 10.1016/j.jbo.2015.06.002. eCollection 2015 Sep.
3
Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Free Radic Biol Med. 2006 May 1;40(9):1483-93. doi: 10.1016/j.freeradbiomed.2005.10.066. Epub 2005 Dec 9.
4
Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Hum Pathol. 2005 Sep;36(9):945-54. doi: 10.1016/j.humpath.2005.07.005.
5
Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
PLoS One. 2016 May 10;11(5):e0154680. doi: 10.1371/journal.pone.0154680. eCollection 2016.
6
A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. doi: 10.1006/bbrc.1999.0252.
7
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.
Endocr Rev. 1999 Jun;20(3):345-57. doi: 10.1210/edrv.20.3.0367.
8
The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
Leuk Lymphoma. 2004 Jun;45(6):1111-8. doi: 10.1080/10428194310001593193.
9
Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Transl Res. 2014 Aug;164(2):139-48. doi: 10.1016/j.trsl.2014.03.005. Epub 2014 Mar 21.
10
Is vitamin D deficiency behind the scenes for high incidence of Giant cell tumor amongst the Indian population? Unraveling the vitamin D - RANKL association.
Med Hypotheses. 2019 Feb;123:67-71. doi: 10.1016/j.mehy.2018.12.010. Epub 2018 Dec 21.
引用本文的文献
1
Giant Cell Tumors of the Bone: Changes in Image Features after Denosumab Administration.
Magn Reson Med Sci. 2018 Oct 10;17(4):325-330. doi: 10.2463/mrms.mp.2017-0072. Epub 2018 Feb 1.
2
RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.
Tumour Biol. 2016 Jul;37(7):9099-110. doi: 10.1007/s13277-015-4761-8. Epub 2016 Jan 14.
本文引用的文献
1
The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase.
Nature. 2015 Jun 4;522(7554):106-110. doi: 10.1038/nature14492. Epub 2015 May 27.
2
Risk factors for pulmonary metastases from giant cell tumor of bone.
J Bone Joint Surg Am. 2015 Mar 4;97(5):420-8. doi: 10.2106/JBJS.N.00678.
3
RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?
Oncology. 2015;88(4):257-60. doi: 10.1159/000369975. Epub 2014 Dec 17.
4
Impact of RANK signalling on survival and chemotherapy response in osteosarcoma.
Pathology. 2014 Aug;46(5):411-5. doi: 10.1097/PAT.0000000000000116.
5
Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
J Bone Miner Res. 2014 Jun;29(6):1431-45. doi: 10.1002/jbmr.2182.
6
WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition.
Pathology. 2014 Feb;46(2):95-104. doi: 10.1097/PAT.0000000000000050.
7
Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.
Paediatr Drugs. 2014 Feb;16(1):21-8. doi: 10.1007/s40272-013-0051-3.
8
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.
J Clin Endocrinol Metab. 2013 Nov;98(11):4483-92. doi: 10.1210/jc.2013-1597. Epub 2013 Aug 26.
9
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
Lancet Oncol. 2013 Aug;14(9):901-8. doi: 10.1016/S1470-2045(13)70277-8. Epub 2013 Jul 16.
10
Giant cell tumor of bone.
J Am Acad Orthop Surg. 2013 Feb;21(2):118-26. doi: 10.5435/JAAOS-21-02-118.
Zotero 插件